Page 3 - Scientific Library
2 new validated anti-PGP 9.5 antibodies for neuroscience research
Protein Gene Product 9.5 (PGP 9.5) is an abundant cytoplasmic neuron and neuroendocrine-cell specific protein. Over the years, this deubiquitinating enzyme (a.k.a. Ubiquitin Carboxy-terminal Hydrolase
How to activate or inhibit autophagy?
The term Autophagy was introduced by Christian de Duve during the Ciba Foundation Symposium on Lysosomes – which was held in London in February 1963. In 1974 he was honoured with
Sekisui XenoTech Awarded Cryopreservation Patent for Cryostax single freeze hepatocytes
Sekisui XenoTech has just been issued U.S. Patent No. 9,642,355 for the “cryopreservation of cells and subcellular fractions,” specifically related to Sekisui XenoTech’s CryostaX®
ADME-Tox: liver fractions with High Aldehyde Oxidase and Xanthine Oxidase Activity
Sekisui XenoTech has just established a method for high Aldehyde Oxidase and Xanthine Oxidase activity in pooled Human liver test systems.
These new test systems (Pooled Human Liver
Tips for primary cell culture
Functionality and viability of primary cells can be impaired by incorrect thawing procedures, storage or culture conditions. It's generally admitted that applying the same protocols as
Bioactive neuronal lipid mediators: a focus on Synaptamide
Focus Biomolecules produces a broad range of bioactive lipid mediators as well as many small molecule inhibitors of numerous lipid metabolic pathways for use as cellular
Recombinant CYP Bactosomes: versatile formats for many ADME applications
Recombinant CYPs are commonly used in ADME-Tox studies as in vitro tools, mostly for reaction phenotyping, enzyme inhibition screening, clearance and metabolite ID.
"Research
Subcellular fractions for ADME studies: broad custom capacities with strong expertise
Over the years, Sekisui XenoTech has built up a strong expertise in preparing subcellular fractions for ADME applications.
There is
Fatty Liver Disease Research: new Tissue Arrays and microsome pool
Sekisui XenoTech now offers human liver tissue microarrays (TMA) and a microsomal pool for studying and developing new treatments for fatty liver disease (FLD). The